Navigation Links
India Not A Guinea Pig For Clinical Trials: Ramadoss

Asserting India is "guarded" on issues related to clinical trials, Union Minister for Health and Family Welfare Anbumani Ramadoss has denied that the country has 'opened out as a guinea pig'//.

'If you do clinical trials in India you have to be transparent. We are very, very guarded. We will not allow our population to suffer,' Ramadoss told reporters at the Indian Embassy here.

'We have laws and we are going to strengthen them,' the visiting Minister said maintaining that India does not allow experimentation on humans and only Phase 2 of clinical trials were allowed with Phase 1 having to be in the country of origin.

The Minister held high level consultations at the National Institutes of Health and the National Cancer Institute, and also a meeting with the Pharmacy Association in Washington.

Ramadoss also visited the prestigious Johns Hopkins University in Baltimore, Maryland. He noted that the John Hopkins facility in Baltimore and India have had a long history of association by way of student exchanges and faculty training.

Ramadoss is scheduled to have a meeting with Secretary of Health and Human Services Michael Leavitt today to discuss issues related to health research with an accent on occupational and environmental health.

Ramadoss said a 'lot of progress' has been made between the United States and India on different fronts especially in health care and vaccines since his visit here last year.

Source:PTI News
'"/>




Page: 1

Related medicine news :

1. Is Diabetes the Leading Cause of Kidney Failure in India
2. AIDS Disaster in India is Imminent
3. Indian Prime Minister has successful Knee Replacement Surgery
4. International community warns India on HIV situation
5. India takes on foot-and-mouth disease by vaccinating animals
6. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
7. India to benefit from pharma companies move
8. Healthcare sector is now a multi billion-dollar industry in India
9. The World Bank funds private Hospital in India
10. Parke-Davis (India) runs into rough weather – Court orders attachment of asset
11. Indian Doctor granted US patent on organ regeneration
Post Your Comments:
Breaking Medicine Technology:Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 2Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 3Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 4Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 5Veran Medical Receives FDA Clearance to Market Electromagnetic Navigated Bronchoscopy Product: The SPiN Drive(TM) System 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3FDA Announces Plans for LASIK Quality of Life Project 59587 1FDA Announces Plans for LASIK Quality of Life Project 59587 2FDA Announces Plans for LASIK Quality of Life Project 59587 3FDA Warns of Unapproved and Illegal H1N1 Drug Products Purchased Over the Internet 59582 1FDA Warns of Unapproved and Illegal H1N1 Drug Products Purchased Over the Internet 59582 2FDA Warns of Unapproved and Illegal H1N1 Drug Products Purchased Over the Internet 59582 3BioMed Realty Trust to Report 2009 Third Quarter Results 59577 1BioMed Realty Trust to Report 2009 Third Quarter Results 59577 2
Other Medicine Technology:New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 2New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 3New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 4New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 5New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 6New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 7New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 8New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 9New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 10New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 11New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 12New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 13New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 14QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy 2QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy 3